The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.
The large-scale public health study is expected to bring clarity to the global medical community regarding the benefits of 12 versus 30 months of dual antiplatelet therapy in patients receiving drug-eluting stents to address coronary artery lesions.
Laura Mauri, principal investigator of the DAPT Study and chief scientific officer of HCRI, said: “The expansion of the DAPT Study into the EU is an important milestone in support of our goal of enrolling over 20,000 subjects and obtaining a diversity of data that reflects real-world clinical practice.”
Gabriel Steg, DAPT national coordinator for France, DAPT executive committee member, and an interventional cardiologist at Hospital Bichat in Paris, said: “The DAPT Study addresses a critical gap in current scientific evidence. This international study will help understand the benefits and the risks associated with prolonged dual antiplatelet therapy beyond one year after stenting.”